Form 4: Rigel Pharmaceuticals Executive Acquires Shares and Options
SEC Form 4 Filing
Lisa Rojkjaer, EVP and Chief Medical Officer at Rigel Pharmaceuticals, acquired shares and stock options on January 29, 2025, as part of her compensation.
Summary
- Lisa Rojkjaer, the EVP and Chief Medical Officer of Rigel Pharmaceuticals, acquired 19,717 shares of common stock through the vesting of a Restricted Stock Unit award.
- These shares will vest annually over three years, starting on February 10, 2026.
- Additionally, Ms. Rojkjaer acquired an option to purchase 14,788 shares of common stock at an exercise price of $22.49.
- The stock options vest monthly over three years from the vesting commencement date of January 29, 2025.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with shareholders. There are no negative implications.
Positives
- The acquisition of shares and options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
This type of stock and option grant is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are standard compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
- Vesting schedules of three years are also typical, aligning executive compensation with long-term company performance.
- Companies like Gilead Sciences, Amgen, and Biogen also use similar equity-based compensation plans for their executives.
Stakeholder Impact
- The stock and option grants are likely to be viewed positively by shareholders as they align executive interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of the transaction where shares and stock options were acquired. |
| 01/29/2025 | Vesting commencement date for the stock options. |
| 02/10/2025 | Start date for the annual vesting of the Restricted Stock Units. |
| 02/10/2026 | First annual vest date for the Restricted Stock Units. |
| 01/31/2025 | Date the form was signed. |
| 01/29/2035 | Expiration date of the stock options. |
Keywords
Rigel Pharmaceuticals, stock options, restricted stock units, insider trading, executive compensation, share acquisition, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.